{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:06:19Z","timestamp":1793815579840,"version":"4.6.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.esmoop.2021.100074","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T03:45:25Z","timestamp":1614311125000},"page":"100074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer"],"prefix":"10.1016","volume":"6","author":[{"given":"J.","family":"Delgado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vleminckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sarac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Enzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pignatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100074_bib1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2021.100074_bib2","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2021.100074_bib3","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100074_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.esmoop.2021.100074_bib5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.esmoop.2021.100074_bib6","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ijc.27725","article-title":"Breast cancer survival in the US and Europe: a CONCORD high-resolution study","volume":"132","author":"Allemani","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2021.100074_bib7","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3390\/cancers12061578","article-title":"Low prevalence of HER2-positive breast carcinomas among screening detected breast cancers","volume":"12","author":"Lopez-Garcia","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2021.100074_bib8","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/07357907.2010.496759","article-title":"Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US","volume":"28","author":"Cronin","year":"2010","journal-title":"Cancer Invest"},{"key":"10.1016\/j.esmoop.2021.100074_bib9","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","article-title":"Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019","volume":"30","author":"Burstein","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100074_bib10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100074_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","article-title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Chan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100074_bib12","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100074_bib13","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jamaoncol.2015.6113","article-title":"Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis","volume":"2","author":"Broglio","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2021.100074_bib14","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer","volume":"23","author":"Buzdar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100074_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2021.100074_bib16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2021.100074_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-015-3479-z","article-title":"Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials","volume":"152","author":"Loibl","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2021.100074_bib18","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100074_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100074_bib20","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100074_bib21","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2014.58.7782","article-title":"Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer","volume":"33","author":"Krop","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100074_bib22","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","article-title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system","volume":"25","author":"Hudis","year":"2007","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:27:13Z","timestamp":1761856033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921000302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2059702921000302"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100074","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100074"}}